Tempus
Tempus is an American biotechnology company that provides data and AI services for the healthcare industry. The company collects genomic data from patients, organizes it, and provides insights with the help of machine learning. It has 3.5+ million patient records in its oncology dataset. Tempus' products and services are used in oncology, neurology, life sciences and infectious disease research to provide patients with personalized, targeted therapies.
Tempus offers services both directly to patients and through physicians. The company is headquartered in Chicago, Illinois.
NewsHeat chart
- Week
- Month
- Year
- Media news
- Corp news
The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice
Company Valuation
- Valuation
- Share Price
- Cumulative Funding
The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.
*** - To view the data, please log into your account or create a new one.
News related to Tempus170
Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development - Tempus
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaboration with Takeda (TSE:4502/NYSE:TAK) that takes a data-first approach to research a...
Tempushttps://www.tempus.com/news/tempus-announces-expansion-of-collaboration-with-takeda-to-leverage-multimodal-real-world-datasets-and-biological-model-systems-in-oncology-research-and-development/Tempus Announces Four Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2024 - Tempus
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced four abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2024,...
Tempushttps://www.tempus.com/news/pr/tempus-announces-four-abstracts-accepted-for-presentation-at-the-european-society-for-medical-oncology-congress-2024/Tempus Launches Beta Version of olivia, its AI-enabled Personal Health Concierge App for Patients - Tempus
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the beta launch of a patient-facing app, olivia, an AI-enabled personal health concierge to empower individuals ...
Tempushttps://www.tempus.com/news/pr/tempus-launches-beta-version-of-olivia-its-ai-enabled-personal-health-concierge-app-for-patients/Tempus Announces Real World Data Collaboration with BioNTech - Tempus
The strategic collaboration will leverage Tempus’ large multimodal datasets to enhance BioNTech’s next-generation oncology pipeline Tempus AI, Inc. (NASDAQ: TEM, “Tempus”), a technology company leading the adoption of AI to advance precision medicine and ...
Tempushttps://www.tempus.com/news/tempus-announces-real-world-data-collaboration-with-biontech/Tempus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference - Tempus
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4th, held in New York, N...
Tempushttps://www.tempus.com/news/tempus-to-present-at-the-morgan-stanley-22nd-annual-global-healthcare-conference/